ClinicalTrials.gg
CompletedNCT01493427Updated May 19, 2014Results posted

Efficacy of Changing to TRAVATAN® From Prior Therapy

A Phase 4 interventional study of Travoprost 0.004% in Open-Angle Glaucoma and Ocular Hypertension, sponsored by Alcon Research. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-05-19.

Sponsored by Alcon Research (part of Alcon) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
202
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 46 studies testing travoprost in Glaucoma, Open-Angle — 2 open to participants now, 3 under way, 1 of them phase 3. Travoprost · Glaucoma, Open-Angle.

Enrollment
13th of 45
202 · median 135
Started
2011
with 8 others
Phase 4
22 of 46
2 open now
Registered
33rd of 46
by date
Lead sponsor
29 of 46
Alcon Research

Among the 46 studies testing travoprost in Glaucoma, Open-Angle, this one is the 13th largest by enrollment of the 45 interventional ones that give a count, is one of 9 that started in 2011, is one of 22 in phase 4, and was the 33rd registered.

Glaucoma, Open-Angle

924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.

Browse Glaucoma, Open-Angle studies →

Open to participants now

2 of the 46 studies testing travoprost in Glaucoma, Open-Angle are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About travoprost

Travoprost: first FDA approval 2001 (TRAVATAN), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 82 Glaucoma, Open-Angle studies recruiting now, 63 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies testing travoprost in Glaucoma, Open-Angle, or all of them as a file.
02

Study summary

The purpose of this study was to assess the efficacy and tolerability of TRAVATAN® Solution without benzalkonium chloride (BAK) in patients previously on latanoprost 0.005% or bimatoprost 0.01% ophthalmic solution monotherapy.

03

Conditions studied

  • Open-Angle Glaucoma
  • Ocular Hypertension

Keywords

  • Glaucoma
  • OAG
  • OHT
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical diagnosis of ocular hypertension or open-angle glaucoma in at least one eye.
  • Be on either latanoprost 0.005% or bimatoprost 0.01% ophthalmic solution monotherapy (including BAK-containing generics) for at least four weeks prior to Screening visit.
  • Would benefit from a switch to TRAVATAN® Solution without BAK containing Polyquad® Preservative due to tolerability issues, in the opinion of the investigator.
  • IOP considered to be safe (in the opinion of the investigator), in both eyes, in such a way that assured clinical stability of vision and the optic nerve throughout the study period.
  • Willing to discontinue the use of all other ocular hypotensive medications prior to receiving the study medication for the entire course of the study.
  • Best corrected Snellen visual acuity of 6/60 (20/200, 1.0 LogMAR) or better in each eye
  • Other protocol-defined inclusion criteria may apply.

Exclusion criteria

Exclusion Criteria:

  • Known medical history of allergy, , or poor tolerance to any component of the preparations to be used in this study deemed in the opinion of the Principal Investigator.
  • Any abnormality preventing reliable applanation tonometry in either eye.
  • Severe dry eye or related which has been or currently is being treated with the use of punctal plugs, punctal cautery, Restasis®, or topical ocular .
  • Any clinically significant, serious, or severe medical condition.
  • Intraocular conventional surgery or laser surgery in either eye less than three months prior to Screening Visit.
  • Risk of visual field or visual acuity worsening as a consequence of participation in the study, in the investigator's best judgment.
  • Progressive retinal or optic nerve disease from any cause.
  • Women who are pregnant, lactating.
  • Women not using reliable means of .
  • Use of any systemic medication known to affect IOP which has not been on stable course for at least 7 days prior to Screening Visit.
  • Any clinically significant, serious, or severe medical condition.
  • Participation in any other study within 30 days of Screening Visit.
  • Other protocol-defined exclusion criteria may apply.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
202 participants (actual)

Study arms

  • Experimental
    TRAVATAN® BAK-free

    Travoprost 0.004%, 1 drop self-administered to the study eye(s) once daily, every evening at around 8:00 pm, for 12 weeks

    Drug: Travoprost 0.004%

Interventions

  • Travoprost 0.004% without benzalkonium chloride (BAK), containing Polyquad (PQ) preservative

    Also known as: TRAVATAN® BAK-free

06

What researchers measure

Primary outcomes

  1. Mean Change in Intraocular Pressure (IOP) at 12 Weeks From Prior Therapy (Baseline)

    IOP (fluid pressure inside the eye) was measured by Goldmann applanation tonometry. A higher IOP can be a greater risk for developing glaucoma or glaucoma progression (leading to optic nerve damage). A more negative change indicates a greater amount of improvement. One eye was chosen as the study eye, and only data from the study eye were used for the efficacy analysis.

    Time frame: Baseline, Week 12

Secondary outcomes

  1. Percentage of Patients With Target IOP (≤18 mmHg) at 12 Weeks

    IOP (fluid pressure inside the eye) was measured by Goldmann applanation tonometry. A higher IOP can be a greater risk for developing glaucoma or glaucoma progression (leading to optic nerve damage). One eye was chosen as the study eye, and only data from the study eye were used for the efficacy analysis.

    Time frame: Week 12

07

Results

Posted May 9, 2014

Participant flow

Subjects were recruited from 15 investigative sites located in Europe: Belgium (2); Spain (6); Italy (4); Sweden (3).

Participant flow — Overall Study
MilestoneTRAVATAN® BAK-free
Started199
Completed179
Not completed20
Withdrew: Adverse event10
Withdrew: Personal reasons4
Withdrew: Lost to follow-up2
Withdrew: Inability to follow instructions2
Withdrew: Other2

Outcome measures

PrimaryMean Change in Intraocular Pressure (IOP) at 12 Weeks From Prior Therapy (Baseline)

IOP (fluid pressure inside the eye) was measured by Goldmann applanation tonometry. A higher IOP can be a greater risk for developing glaucoma or glaucoma progression (leading to optic nerve damage). A more negative change indicates a greater amount of improvement. One eye was chosen as the study eye, and only data from the study eye were used for the efficacy analysis.

Time frame:
Baseline, Week 12
Reported as:
Mean · millimeters mercury (mmHg)
Mean Change in Intraocular Pressure (IOP) at 12 Weeks From Prior Therapy (Baseline)
millimeters mercury (mmHg)TRAVATAN® BAK-free
Baseline17.0 ± 3.3
Change from Baseline at Week 12 (n=178)-1.16 ± 2.65
SecondaryPercentage of Patients With Target IOP (≤18 mmHg) at 12 Weeks

IOP (fluid pressure inside the eye) was measured by Goldmann applanation tonometry. A higher IOP can be a greater risk for developing glaucoma or glaucoma progression (leading to optic nerve damage). One eye was chosen as the study eye, and only data from the study eye were used for the efficacy analysis.

Time frame:
Week 12
Reported as:
Number · Percentage of participants
Percentage of Patients With Target IOP (≤18 mmHg) at 12 Weeks
Percentage of participantsTRAVATAN® BAK-free
Percentage of Patients With Target IOP (≤18 mmHg) at 12 Weeks81.2

Adverse events

Collected over Adverse event data were collected and reported in the eCRF at each visit from time of first drug instillation to Week 12. Adverse events were collected for the duration of the study (1 year, 2 months).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
TRAVATAN® BAK-free—4/199 (2%)0/199 (0%)
Most frequent serious events
Most frequent serious events
EventTRAVATAN® BAK-free
Upper gastrointestinal hemmorhageGastrointestinal disorders1/199
Pneumonia pneumococcalInfections and infestations1/199
Respiratory tract infectionInfections and infestations1/199
CholelithiasisHepatobiliary disorders1/199

Baseline characteristics

This reporting group includes all subjects who instilled at least one dose of the test article

Age, Continuous
Age, Continuous(years)TRAVATAN® BAK-free
Mean66.6 ± 11.7
Sex: Female, Male
Sex: Female, Male(Participants)TRAVATAN® BAK-free
Female117
Male82
08

Study locations

No study locations are listed for this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2011, a primary completion of Feb 2013 and a completion of Feb 2013. It does not say whether these dates are actual or estimated.

Results were first posted in May 2014, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 14, 2011
First posted
Dec 16, 2011
Start
Dec 2011
Primary completionActual
Feb 2013
CompletionActual
Feb 2013
Results first posted
May 9, 2014
Last update
May 19, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 19, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01493427
Lead sponsor
Alcon Research
Responsible party
Sponsor
First posted
Dec 16, 2011
Start date
Dec 2011
Primary completion
Feb 2013
Completion
Feb 2013
Results posted
May 9, 2014
Last update
May 19, 2014

Study contacts

Severine Durier, Pharm.D
study director · Alcon Research

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Travoprost

Start the discussion